What is PT-141?
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist FDA-approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors which work on blood vessels, PT-141 acts on melanocortin receptors in the central nervous system, making it one of the first centrally-acting agents for sexual dysfunction.
How It Works
PT-141 activates melanocortin-4 receptors (MC4R) in the brain, which are involved in sexual arousal pathways. It was originally developed from Melanotan II but was isolated for its sexual function effects without the tanning properties.
Reconstitution
- 2 mg → 1 mL BAC water
- 5 mg → 2 mL BAC water
- 10 mg → 3 mL BAC water
Dosing
The FDA-approved dose is 1.75 mg subcutaneously, administered at least 45 minutes before anticipated activity. Maximum frequency: once per 24 hours, no more than 8 times per month. Research protocols range from 0.5–2 mg. Nausea is the most common side effect, particularly at higher doses.
FDA-approved prescription medication (Vyleesi). Educational purposes only.